CNC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CN

Mkt Cap

$34.16B

Volume

2.56M

Next Earnings

October 27th

Loading chart

CN

CNCCentene Corporation

CNC

Pay with—

Available Balance0.00

CN

Mkt Cap

$34.16B

Volume

2.56M

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy?UnitedHealth Group reported Q3 adjusted earnings of $4.69 per share, beating estimates by 13.9% with a 60.6% year-over-year increase. The company raised its 2026 EPS outlook to at least $20.50, driven by improved margins and lower medical costs. However, membership declined to 48.3 million from 50.1 million, raising questions about long-term sustainability. Optum also showed strong recovery with margins expanding to 5.6%. The stock carries a Zacks Rank #2 (Buy) rating with valuation below historical medians.Zacks Investment Research · Oct 16, 2026

Can UNH's Focus on Special Needs Plans Strengthen Medicare Growth?UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings.Zacks Investment Research · Oct 15, 2026

Centene's Gold Card Push Could Ease Costs - But Will Savings Follow?Centene Corporation will launch its National Performance-Based Gold Card Program nationwide in November 2026, covering over 160,000 providers and allowing qualifying providers to bypass prior authorization for eligible outpatient services. The initiative aims to reduce administrative burden and processing costs while maintaining clinical oversight. Centene trades at 13.13x forward earnings with 2026 EPS estimated to grow 135.1% to $4.89, though the stock carries a Zacks Rank #4 (Sell) rating.Zacks Investment Research · Oct 14, 2026

Centene vs. Molina: Which Managed Care Stock Has More Upside?Centene (CNC) and Molina Healthcare (MOH) are compared as major players in U.S. managed care with significant Medicaid exposure. Centene benefits from diversified operations across Medicaid, Medicare, and Marketplace plans, improving margins, and strong financial position with lower leverage. Molina faces near-term profitability pressures from reimbursement challenges and Marketplace headwinds, though its expanding Medicaid contracts and Medicare Duals strategy offer long-term growth. Analysts favor Centene for near-term upside based on stronger earnings estimates, valuation, and recent stock performance.Zacks Investment Research · Oct 12, 2026

Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits?Oscar Health (OSCR) has surged 130% year-to-date driven by ACA marketplace expansion and plans to enter 150+ metro areas by 2027. However, the stock trades at a premium 4.94 price-to-book ratio versus the industry average of 2.64, and long-term profitability depends on disciplined underwriting and cost management rather than favorable policy conditions alone. Concentration risk from ACA exposure and potential subsidy policy changes pose headwinds.Zacks Investment Research · Oct 8, 2026

Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?Centene Corporation (CNC) has surged 57% year-to-date, outperforming peers and the broader market, driven by improving Medicaid margins and strengthened Marketplace profitability. The company raised 2026 adjusted EPS guidance above $4.80, though approximately 50 cents per share will not recur in 2027. Trading at 12.34X forward earnings below industry average, CNC carries a Hold rating as investors await evidence that margin gains can sustain into 2027 amid risks including membership losses and policy exposure.Zacks Investment Research · Oct 7, 2026

Centene Narrows Medicare Advantage Footprint as Costs Remain ElevatedCentene Corporation is restructuring its Medicare Advantage business for 2027, pulling standard MA plans from 344 counties and exiting Hawaii, Oklahoma, and Tennessee due to unfavorable economics. The company is shifting focus toward Special Needs Plans and dual-eligible members while leveraging its Part D platform. Competitors UnitedHealth and Humana are also refining their MA footprints with similar selective approaches as medical and pharmacy costs pressure plan profitability.Zacks Investment Research · Oct 6, 2026

Buy 5 Growth Stocks to Boost Your Portfolio in Q4 After a Mixed Q3Zacks Investment Research identifies five growth stocks with Zacks Rank #1 (Strong Buy) ratings expected to perform well in Q4 2026, supported by softer inflation, lower bond yields, and reduced crude oil prices. The picks include Quanta Services (infrastructure/AI data centers), FormFactor (semiconductor testing), Semtech (data center networking), Centene (healthcare services), and Roku (streaming advertising), all showing strong revenue and earnings growth projections.Zacks Investment Research · Oct 6, 2026

Oscar Health Trading at a Premium: Why Should You Still Buy It?Oscar Health (OSCR) trades at a premium valuation of 4.65x book value but has gained 142.5% year-to-date, driven by strong membership growth to 2.96 million, 70% revenue surge to $4.88 billion in Q2, and improved profitability. The company targets 20% revenue CAGR through 2027 and 5% operating margin next year, supported by its technology-driven platform and expansion into 150+ new metropolitan areas. Analysts maintain optimistic sentiment with upward earnings estimate revisions.Zacks Investment Research · Oct 5, 2026

Are Investors Undervaluing Centene (CNC) Right Now?Zacks highlights Centene (CNC) as a compelling value stock pick, citing its Zacks Rank #1 (Strong Buy) rating and 'A' Value grade. The company trades at a P/E ratio of 12.35 versus its industry average of 14.96, with a PEG ratio of 0.82 and P/S ratio of 0.15, suggesting the stock is undervalued relative to its earnings growth prospects and industry peers.Zacks Investment Research · Oct 5, 2026

to start trading

CN

CNCCentene Corporation

CNC

Pay with—

Available Balance0.00

Your PositionYou don't own any CNC yet.

Related Tickers

Earnings